Navigation Links
The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Date:9/1/2010

COLD SPRING HARBOR, N.Y., Sept. 1 /PRNewswire/ -- The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available online now at ASCOPost.com and appear in the September issue of the publication.

"It is important that the breast cancer community rest assured that ODAC is an independent, unbiased panel of experts in oncology whose mission is to provide their best objective scientific and clinical recommendations to the FDA for drug approval," said ODAC Chair, Wyndham Wilson, MD, PhD. Dr. Wilson is Chief of the Lymphoid Therapeutics Section of the Center for Cancer Research, National Cancer Institute.

Bevacizumab is currently approved in combination with paclitaxel for the first-line treatment of advanced HER2-negative breast cancer, based on encouraging results of the E2100 trial (N Engl J Med 357:2666-2676, 2007). The FDA provisionally granted accelerated approval but requested confirmatory data from the manufacturer, Genentech. In November 2009, Genentech supplied the results of the AVADO (J Clin Oncol 28:3239-3247, 2010) and RIBBON-1 trials (J Clin Oncol 27(abstract 1005), 2009). On July 20, 2010, ODAC recommended against conversion to full approval.

Joanne Mortimer, MD, a member of ODAC, who voted to approve bevacizumab in advanced breast cancer in December 2007 based on the E2100 study, said, "The additional data from AVADO and RIBBON-1 supported an increased response rate, but also confirmed the increased toxicity and lack of survival advantage with bevacizumab. Like the majority of panel [ODAC] members, I could not recommend approval." Dr. Mortimer is Director of the Women's Cancers' Program and Professor of Medical Oncolo
'/>"/>

SOURCE Harborside Press
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
3. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
4. NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
5. BIA Publishes White Paper: ISO 9000 Role in Document Review, Emphasizes Quality Equals Defensibility
6. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
7. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
8. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
9. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
10. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
11. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...
(Date:5/23/2013)... , May 23, 2013 Amgen (NASDAQ: ... th Annual  Healthcare Conference on Thursday, May 30, 2013, ... , beginning at 9:20 a.m. Eastern Daylight Time. ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... European Society for Therapeutic Radiology and Oncology (ESTRO) exhibition, ... will demonstrate advanced solutions that provide clinicians with the ... worldwide. This includes Elekta,s new RFID system, Identify*, which ... of patient identification and set up. ...
... 2011 Pearl Therapeutics Inc. made three presentations ... 2011) meeting in Berlin this week elucidating the ... particle-based metered dose inhaler (MDI) development approach.  The ... cosuspension platform , which facilitates forming stable ...
Cached Medicine Technology:Elekta to Demonstrate Advanced Solutions for Managing Cancer Safely and Effectively at ESTRO 2011 2Elekta to Demonstrate Advanced Solutions for Managing Cancer Safely and Effectively at ESTRO 2011 3Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products 2Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products 3Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products 4Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products 5
(Date:5/25/2013)... May 25, 2013 By working diligently ... declared the integration of the 2012 Lamborghini Aventador into ... the latest entrant in the list of vehicles lined ... vehicle is all set to thrill automobile lovers in ... power and spectacular looks, the 2012 Lamborghini Aventador comes ...
(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra ... women that ever lived. Cleopatra’s legendary beauty moved nations ... most powerful men in her time. Cleopatra was also ... her skin glowing and fresh, from her legendary milk ... oil and cyprus grass. , Cleopatra was said to ...
(Date:5/25/2013)... 25, 2013 For college students, ... week. Increasingly, they are turning to prescription stimulants ... study. For more on this, go to ... facility, warns that students who pick up Adderall, ... risk for developing a physical and psychological dependency. ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 HealthCrave ... that is unique in that it doesn’t just ... focuses on treating what causes the noticeable signs ... physician Dr. James D. Weiss, M.D., the center ... aging process while helping patients to live longer, ...
(Date:5/24/2013)... A recent study by research group Harris Interactive found that ... season. Almost 138 million people are fearful of pulling on ... issues and a quarter admit they feel pressured to lose ... those anxious about their size consider the over the counter ... effort to improve diet and exercise habits ahead of peak ...
Breaking Medicine News(10 mins):Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Anti-Aging Center Offers Advanced Treatment that Controls the Aging Process from Within 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 2Health News:PhenObestin 37.5 Can Help Make Bathing Suit Season Less Stressful 3
... HealthDay Reporter , MONDAY, Sept. 26 (HealthDay News) ... brain size and more problems with thinking skills as people ... who suffer from B-12 deficiencies may be greater than thought ... not be accurate, said Christine C. Tangney, lead author of ...
... study shows that 145,000 deaths could be averted in ... stronger tobacco control policies. This set of policies, as ... Organisation, consists of increasing tobacco taxes to 70% of ... public places, a complete marketing ban, well-funded tobacco control ...
... cancer patients who use a new combination of the ... Gy) before surgery have an 88 percent chance of ... randomized trial presented at the plenary session, October 3, ... Society for Radiation Oncology (ASTRO). "The results of ...
... 26, 2011 Notable levels of calcium buildup in coronary ... in people with diabetes and metabolic syndrome, according to a ... The researchers also found that individuals with diabetes or metabolic ... as low as many without these conditions. Supported by ...
... treatment for one form of albinism? Individuals ... pale skin, and light-colored irises because they have none, or ... and eyes. Affected individuals have impaired eyesight and a substantially ... to attempts to correct eyesight and counseling to promote the ...
... health challenges earlier than their fellow seniors, researchers ... lives of 8,700 older people, a Case Western ... reported physical limitations by African American women in ... finding surfaced as researchers looked generally at how ...
Cached Medicine News:Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 2Health News:Could Too Little Vitamin B-12 Shrink the Aging Brain? 3Health News:Stronger tobacco control policy in the Netherlands would save thousands of lives 2Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:JCI online early table of contents: September 26, 2011 2Health News:JCI online early table of contents: September 26, 2011 3Health News:JCI online early table of contents: September 26, 2011 4Health News:JCI online early table of contents: September 26, 2011 5Health News:JCI online early table of contents: September 26, 2011 6Health News:JCI online early table of contents: September 26, 2011 7Health News:African-American women develop functional challenges earlier than others 2Health News:African-American women develop functional challenges earlier than others 3
The AutoSet Respond offers ResMeds unique AutoSet algorithm and product quality in a convenient, affordable model. The AutoSet algorithm responds to the patients pressure needs on a breath-by-breath ...
These products are primarily for use with paediatric patients and for patients with difficult veins....
... helps protect you against needlestick injury. Its ... exposure to a contaminated needle, provides easy ... for use in high-risk environments. The one-handed ... for activation of the safety mechanism while ...
... System provides the capability to ... middle of surgery while retaining ... incision. The system is also ... for large patients while remaining ...
Medicine Products: